An anti-interleukin-1 (anti-IL-1) alpha antibody called MABp1 has been shown to significantly improve response in patients with metastatic colorectal cancer (mCRC) in a phase III clinical trial that adopted symptom control as criteria for objective response (OR).
Regorafenib significantly improves overall survival (OS) and progression-free survival (PFS) in patients with intermediate or advanced hepatocellular carcinoma (HCC) whose disease progressed on sorafenib treatment, according to results of the phase III RESOURCE trial presented at the European Society for Medical Oncology (ESMO) 18th World Congress on Gastrointestinal Cancer.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.